Selected research
Market Outlook & Growth Opportunities
Global Sickle Cell Disease Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Sickle Cell Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Sickle Cell Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Sickle Cell Disease Drug market include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Sickle Cell Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Sickle Cell Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Sickle Cell Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sickle Cell Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Sickle Cell Disease Drug Segment by Company
Global Blood Therapeutics Inc
Gilead Sciences Inc
Genethon SA
Gamida Cell Ltd
Errant Gene Therapeutics LLC
Editas Medicine Inc
Daiichi Sankyo Co Ltd
CSL Ltd
CRISPR Therapeutics
Calimmune Inc
Bristol-Myers Squibb Co
bluebird bio Inc
Bioverativ Inc
Bio Products Laboratory Ltd
ArQule Inc
Annexin Pharmaceuticals AB
Angiocrine Bioscience Inc
Addmedica SAS
Acceleron Pharma Inc
Sickle Cell Disease Drug Segment by Type
CAL-H
DRX-194
CTX-001
BIVV-003
ARQ-092
Others
Sickle Cell Disease Drug Segment by Application
Hospital
Clinic
Others
Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Sickle Cell Disease Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Sickle Cell Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Sickle Cell Disease Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Sickle Cell Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sickle Cell Disease Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sickle Cell Disease Drug industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Sickle Cell Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Sickle Cell Disease Drug Industry Trends
Table 2. Sickle Cell Disease Drug Industry Drivers
Table 3. Sickle Cell Disease Drug Industry Opportunities and Challenges
Table 4. Sickle Cell Disease Drug Industry Restraints
Table 5. Global Sickle Cell Disease Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Sickle Cell Disease Drug Revenue Share by Company (2021-2026)
Table 7. Global Sickle Cell Disease Drug Sales Volume by Company (K Units) & (2021-2026)
Table 8. Global Sickle Cell Disease Drug Sales Volume Share by Company (2021-2026)
Table 9. Global Sickle Cell Disease Drug Average Price (US$/Unit) of Company (2021-2026)
Table 10. Global Sickle Cell Disease Drug Company Ranking, (2024-2026) & (USD Million)
Table 11. Global Sickle Cell Disease Drug Key Company Manufacturing Base & Headquarters
Table 12. Global Sickle Cell Disease Drug Company, Product Type & Application
Table 13. Global Sickle Cell Disease Drug Company Establishment Date
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Significant Companies of CAL-H
Table 18. Significant Companies of DRX-194
Table 19. Significant Companies of CTX-001
Table 20. Significant Companies of BIVV-003
Table 21. Significant Companies of ARQ-092
Table 22. Significant Companies of Others
Table 23. Global Sickle Cell Disease Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units)
Table 24. Global Sickle Cell Disease Drug Sales Volume by Type (2021-2026) & (K Units)
Table 25. Global Sickle Cell Disease Drug Sales Volume by Type (2027-2032) & (K Units)
Table 26. Global Sickle Cell Disease Drug Sales Volume Share by Type (2021-2026)
Table 27. Global Sickle Cell Disease Drug Sales Volume Share by Type (2027-2032)
Table 28. Global Sickle Cell Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 29. Global Sickle Cell Disease Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 30. Global Sickle Cell Disease Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 31. Global Sickle Cell Disease Drug Sales Value Share by Type (2021-2026)
Table 32. Global Sickle Cell Disease Drug Sales Value Share by Type (2027-2032)
Table 33. Significant Companies of Hospital
Table 34. Significant Companies of Clinic
Table 35. Significant Companies of Others
Table 36. Global Sickle Cell Disease Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units)
Table 37. Global Sickle Cell Disease Drug Sales Volume by Application (2021-2026) & (K Units)
Table 38. Global Sickle Cell Disease Drug Sales Volume by Application (2027-2032) & (K Units)
Table 39. Global Sickle Cell Disease Drug Sales Volume Share by Application (2021-2026)
Table 40. Global Sickle Cell Disease Drug Sales Volume Share by Application (2027-2032)
Table 41. Global Sickle Cell Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 42. Global Sickle Cell Disease Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 43. Global Sickle Cell Disease Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 44. Global Sickle Cell Disease Drug Sales Value Share by Application (2021-2026)
Table 45. Global Sickle Cell Disease Drug Sales Value Share by Application (2027-2032)
Table 46. Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 47. Global Sickle Cell Disease Drug Sales by Region (2021-2026) & (K Units)
Table 48. Global Sickle Cell Disease Drug Sales Market Share by Region (2021-2026)
Table 49. Global Sickle Cell Disease Drug Sales by Region (2027-2032) & (K Units)
Table 50. Global Sickle Cell Disease Drug Sales Market Share by Region (2027-2032)
Table 51. Global Sickle Cell Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 52. Global Sickle Cell Disease Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 53. Global Sickle Cell Disease Drug Sales Value Share by Region (2021-2026)
Table 54. Global Sickle Cell Disease Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 55. Global Sickle Cell Disease Drug Sales Value Share by Region (2027-2032)
Table 56. Global Sickle Cell Disease Drug Market Average Price (US$/Unit) by Region (2021-2026)
Table 57. Global Sickle Cell Disease Drug Market Average Price (US$/Unit) by Region (2027-2032)
Table 58. Global Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Table 59. Global Sickle Cell Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 60. Global Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 61. Global Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 62. Global Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units)
Table 63. Global Sickle Cell Disease Drug Sales Market Share by Country (2027-2032)
Table 64. Global Sickle Cell Disease Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 65. Global Sickle Cell Disease Drug Sales Value Market Share by Country (2021-2026)
Table 66. Global Sickle Cell Disease Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 67. Global Sickle Cell Disease Drug Sales Value Market Share by Country (2027-2032)
Table 68. Global Blood Therapeutics Inc Company Information
Table 69. Global Blood Therapeutics Inc Business Overview
Table 70. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
Table 72. Global Blood Therapeutics Inc Recent Development
Table 73. Gilead Sciences Inc Company Information
Table 74. Gilead Sciences Inc Business Overview
Table 75. Gilead Sciences Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
Table 77. Gilead Sciences Inc Recent Development
Table 78. Genethon SA Company Information
Table 79. Genethon SA Business Overview
Table 80. Genethon SA Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Genethon SA Sickle Cell Disease Drug Product Portfolio
Table 82. Genethon SA Recent Development
Table 83. Gamida Cell Ltd Company Information
Table 84. Gamida Cell Ltd Business Overview
Table 85. Gamida Cell Ltd Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
Table 87. Gamida Cell Ltd Recent Development
Table 88. Errant Gene Therapeutics LLC Company Information
Table 89. Errant Gene Therapeutics LLC Business Overview
Table 90. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
Table 92. Errant Gene Therapeutics LLC Recent Development
Table 93. Editas Medicine Inc Company Information
Table 94. Editas Medicine Inc Business Overview
Table 95. Editas Medicine Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
Table 97. Editas Medicine Inc Recent Development
Table 98. Daiichi Sankyo Co Ltd Company Information
Table 99. Daiichi Sankyo Co Ltd Business Overview
Table 100. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
Table 102. Daiichi Sankyo Co Ltd Recent Development
Table 103. CSL Ltd Company Information
Table 104. CSL Ltd Business Overview
Table 105. CSL Ltd Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. CSL Ltd Sickle Cell Disease Drug Product Portfolio
Table 107. CSL Ltd Recent Development
Table 108. CRISPR Therapeutics Company Information
Table 109. CRISPR Therapeutics Business Overview
Table 110. CRISPR Therapeutics Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
Table 112. CRISPR Therapeutics Recent Development
Table 113. Calimmune Inc Company Information
Table 114. Calimmune Inc Business Overview
Table 115. Calimmune Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Calimmune Inc Sickle Cell Disease Drug Product Portfolio
Table 117. Calimmune Inc Recent Development
Table 118. Bristol-Myers Squibb Co Company Information
Table 119. Bristol-Myers Squibb Co Business Overview
Table 120. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
Table 122. Bristol-Myers Squibb Co Recent Development
Table 123. bluebird bio Inc Company Information
Table 124. bluebird bio Inc Business Overview
Table 125. bluebird bio Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
Table 127. bluebird bio Inc Recent Development
Table 128. Bioverativ Inc Company Information
Table 129. Bioverativ Inc Business Overview
Table 130. Bioverativ Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
Table 132. Bioverativ Inc Recent Development
Table 133. Bio Products Laboratory Ltd Company Information
Table 134. Bio Products Laboratory Ltd Business Overview
Table 135. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
Table 137. Bio Products Laboratory Ltd Recent Development
Table 138. ArQule Inc Company Information
Table 139. ArQule Inc Business Overview
Table 140. ArQule Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. ArQule Inc Sickle Cell Disease Drug Product Portfolio
Table 142. ArQule Inc Recent Development
Table 143. Annexin Pharmaceuticals AB Company Information
Table 144. Annexin Pharmaceuticals AB Business Overview
Table 145. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
Table 147. Annexin Pharmaceuticals AB Recent Development
Table 148. Angiocrine Bioscience Inc Company Information
Table 149. Angiocrine Bioscience Inc Business Overview
Table 150. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
Table 152. Angiocrine Bioscience Inc Recent Development
Table 153. Addmedica SAS Company Information
Table 154. Addmedica SAS Business Overview
Table 155. Addmedica SAS Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Addmedica SAS Sickle Cell Disease Drug Product Portfolio
Table 157. Addmedica SAS Recent Development
Table 158. Acceleron Pharma Inc Company Information
Table 159. Acceleron Pharma Inc Business Overview
Table 160. Acceleron Pharma Inc Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
Table 162. Acceleron Pharma Inc Recent Development
Table 163. Key Raw Materials
Table 164. Raw Materials Key Suppliers
Table 165. Sickle Cell Disease Drug Distributors List
Table 166. Sickle Cell Disease Drug Customers List
Table 167. Research Programs/Design for This Report
Table 168. Authors List of This Report
Table 169. Secondary Sources
Table 170. Primary Sources
List of Figures
Figure 1. Sickle Cell Disease Drug Product Image
Figure 2. Global Sickle Cell Disease Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 4. Global Sickle Cell Disease Drug Sales (2021-2032) & (K Units)
Figure 5. Global Sickle Cell Disease Drug Sales Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Sickle Cell Disease Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 9. CAL-H Image
Figure 10. DRX-194 Image
Figure 11. CTX-001 Image
Figure 12. BIVV-003 Image
Figure 13. ARQ-092 Image
Figure 14. Others Image
Figure 15. Global Sickle Cell Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 16. Global Sickle Cell Disease Drug Sales Volume Share 2021 VS 2025 VS 2032
Figure 17. Global Sickle Cell Disease Drug Sales Volume Share by Type (2021-2032)
Figure 18. Global Sickle Cell Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Sickle Cell Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Sickle Cell Disease Drug Sales Value Share by Type (2021-2032)
Figure 21. Hospital Image
Figure 22. Clinic Image
Figure 23. Others Image
Figure 24. Global Sickle Cell Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 25. Global Sickle Cell Disease Drug Sales Volume Share 2021 VS 2025 VS 2032
Figure 26. Global Sickle Cell Disease Drug Sales Volume Share by Application (2021-2032)
Figure 27. Global Sickle Cell Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 28. Global Sickle Cell Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 29. Global Sickle Cell Disease Drug Sales Value Share by Application (2021-2032)
Figure 30. Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Figure 31. Global Sickle Cell Disease Drug Sales Market Share by Region: 2021 VS 2025 VS 2032
Figure 32. Global Sickle Cell Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 33. Global Sickle Cell Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 34. North America Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 35. North America Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 36. Europe Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 37. Europe Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 38. Asia-Pacific Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 39. Asia-Pacific Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 40. South America Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 41. South America Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 42. Middle East & Africa Sickle Cell Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 43. Middle East & Africa Sickle Cell Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 44. USA Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. USA Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. USA Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. Canada Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. Canada Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. Canada Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Mexico Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Mexico Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Mexico Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Germany Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Germany Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Germany Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. France Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. France Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. France Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. U.K. Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. U.K. Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. U.K. Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Italy Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Italy Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Italy Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. Spain Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. Spain Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. Spain Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Russia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Russia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Russia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. Netherlands Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. Netherlands Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. Netherlands Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. Nordic Countries Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. Nordic Countries Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. Nordic Countries Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. China Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. China Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. China Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Japan Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Japan Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Japan Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. South Korea Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. South Korea Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. South Korea Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. India Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. India Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. India Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Australia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Australia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Australia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Southeast Asia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Southeast Asia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Southeast Asia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Brazil Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Brazil Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Brazil Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Argentina Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Argentina Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Argentina Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Chile Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Chile Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Chile Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. Colombia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. Colombia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. Colombia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Peru Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Peru Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Peru Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Saudi Arabia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Saudi Arabia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Saudi Arabia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Israel Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Israel Arabia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Israel Arabia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. UAE Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 117. UAE Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 118. UAE Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 119. Turkey Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 120. Turkey Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 121. Turkey Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 122. Iran Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 123. Iran Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 124. Iran Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 125. Egypt Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 126. Egypt Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 127. Egypt Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 128. Sickle Cell Disease Drug Value Chain
Figure 129. Manufacturing Cost Structure
Figure 130. Sickle Cell Disease Drug Sales Mode & Process
Figure 131. Direct Comparison with Distribution Share
Figure 132. Distributors Profiles
Figure 133. Years Considered
Figure 134. Research Process
Figure 135. Key Executives Interviewed
Scope & coverage.
Types
- CAL-H
- DRX-194
- CTX-001
- BIVV-003
- ARQ-092
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Global Blood Therapeutics Inc
- Gilead Sciences Inc
- Genethon SA
- Gamida Cell Ltd
- Errant Gene Therapeutics LLC
- Editas Medicine Inc
- Daiichi Sankyo Co Ltd
- CSL Ltd
- CRISPR Therapeutics
- Calimmune Inc
- Bristol-Myers Squibb Co
- bluebird bio Inc
- Bioverativ Inc
- Bio Products Laboratory Ltd
- ArQule Inc
- Annexin Pharmaceuticals AB
- Angiocrine Bioscience Inc
- Addmedica SAS
- Acceleron Pharma Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Sickle Cell Disease Drug Sales Value (2021-2032)
- 1.2.2 Global Sickle Cell Disease Drug Sales Volume (2021-2032)
- 1.2.3 Global Sickle Cell Disease Drug Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Sickle Cell Disease Drug Market Dynamics
- 2.1 Sickle Cell Disease Drug Industry Trends
- 2.2 Sickle Cell Disease Drug Industry Drivers
- 2.3 Sickle Cell Disease Drug Industry Opportunities and Challenges
- 2.4 Sickle Cell Disease Drug Industry Restraints
3 Sickle Cell Disease Drug Market by Company
- 3.1 Global Sickle Cell Disease Drug Company Revenue Ranking in 2025
- 3.2 Global Sickle Cell Disease Drug Revenue by Company (2021-2026)
- 3.3 Global Sickle Cell Disease Drug Sales Volume by Company (2021-2026)
- 3.4 Global Sickle Cell Disease Drug Average Price by Company (2021-2026)
- 3.5 Global Sickle Cell Disease Drug Company Ranking (2024-2026)
- 3.6 Global Sickle Cell Disease Drug Company Manufacturing Base and Headquarters
- 3.7 Global Sickle Cell Disease Drug Company Product Type and Application
- 3.8 Global Sickle Cell Disease Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Sickle Cell Disease Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Sickle Cell Disease Drug Market by Type
- 4.1 Sickle Cell Disease Drug Type Introduction
- 4.1.1 CAL-H
- 4.1.2 DRX-194
- 4.1.3 CTX-001
- 4.1.4 BIVV-003
- 4.1.5 ARQ-092
- 4.1.6 Others
- 4.2 Global Sickle Cell Disease Drug Sales Volume by Type
- 4.2.1 Global Sickle Cell Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Sickle Cell Disease Drug Sales Volume by Type (2021-2032)
- 4.2.3 Global Sickle Cell Disease Drug Sales Volume Share by Type (2021-2032)
- 4.3 Global Sickle Cell Disease Drug Sales Value by Type
- 4.3.1 Global Sickle Cell Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Sickle Cell Disease Drug Sales Value by Type (2021-2032)
- 4.3.3 Global Sickle Cell Disease Drug Sales Value Share by Type (2021-2032)
5 Sickle Cell Disease Drug Market by Application
- 5.1 Sickle Cell Disease Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Sickle Cell Disease Drug Sales Volume by Application
- 5.2.1 Global Sickle Cell Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Sickle Cell Disease Drug Sales Volume by Application (2021-2032)
- 5.2.3 Global Sickle Cell Disease Drug Sales Volume Share by Application (2021-2032)
- 5.3 Global Sickle Cell Disease Drug Sales Value by Application
- 5.3.1 Global Sickle Cell Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Sickle Cell Disease Drug Sales Value by Application (2021-2032)
- 5.3.3 Global Sickle Cell Disease Drug Sales Value Share by Application (2021-2032)
6 Sickle Cell Disease Drug Regional Sales and Value Analysis
- 6.1 Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Sickle Cell Disease Drug Sales by Region (2021-2032)
- 6.2.1 Global Sickle Cell Disease Drug Sales by Region: 2021-2026
- 6.2.2 Global Sickle Cell Disease Drug Sales by Region (2027-2032)
- 6.3 Global Sickle Cell Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Sickle Cell Disease Drug Sales Value by Region (2021-2032)
- 6.4.1 Global Sickle Cell Disease Drug Sales Value by Region: 2021-2026
- 6.4.2 Global Sickle Cell Disease Drug Sales Value by Region (2027-2032)
- 6.5 Global Sickle Cell Disease Drug Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.6.2 North America Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.7.2 Europe Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.9.2 South America Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Sickle Cell Disease Drug Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Sickle Cell Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Sickle Cell Disease Drug Country-level Sales and Value Analysis
- 7.1 Global Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Sickle Cell Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Sickle Cell Disease Drug Sales by Country (2021-2032)
- 7.3.1 Global Sickle Cell Disease Drug Sales by Country (2021-2026)
- 7.3.2 Global Sickle Cell Disease Drug Sales by Country (2027-2032)
- 7.4 Global Sickle Cell Disease Drug Sales Value by Country (2021-2032)
- 7.4.1 Global Sickle Cell Disease Drug Sales Value by Country (2021-2026)
- 7.4.2 Global Sickle Cell Disease Drug Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 France Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 China Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 India Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Sickle Cell Disease Drug Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Sickle Cell Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Sickle Cell Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Global Blood Therapeutics Inc
- 8.1.1 Global Blood Therapeutics Inc Company Information
- 8.1.2 Global Blood Therapeutics Inc Business Overview
- 8.1.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
- 8.1.5 Global Blood Therapeutics Inc Recent Developments
- 8.2 Gilead Sciences Inc
- 8.2.1 Gilead Sciences Inc Company Information
- 8.2.2 Gilead Sciences Inc Business Overview
- 8.2.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
- 8.2.5 Gilead Sciences Inc Recent Developments
- 8.3 Genethon SA
- 8.3.1 Genethon SA Company Information
- 8.3.2 Genethon SA Business Overview
- 8.3.3 Genethon SA Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Genethon SA Sickle Cell Disease Drug Product Portfolio
- 8.3.5 Genethon SA Recent Developments
- 8.4 Gamida Cell Ltd
- 8.4.1 Gamida Cell Ltd Company Information
- 8.4.2 Gamida Cell Ltd Business Overview
- 8.4.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
- 8.4.5 Gamida Cell Ltd Recent Developments
- 8.5 Errant Gene Therapeutics LLC
- 8.5.1 Errant Gene Therapeutics LLC Company Information
- 8.5.2 Errant Gene Therapeutics LLC Business Overview
- 8.5.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
- 8.5.5 Errant Gene Therapeutics LLC Recent Developments
- 8.6 Editas Medicine Inc
- 8.6.1 Editas Medicine Inc Company Information
- 8.6.2 Editas Medicine Inc Business Overview
- 8.6.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
- 8.6.5 Editas Medicine Inc Recent Developments
- 8.7 Daiichi Sankyo Co Ltd
- 8.7.1 Daiichi Sankyo Co Ltd Company Information
- 8.7.2 Daiichi Sankyo Co Ltd Business Overview
- 8.7.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
- 8.7.5 Daiichi Sankyo Co Ltd Recent Developments
- 8.8 CSL Ltd
- 8.8.1 CSL Ltd Company Information
- 8.8.2 CSL Ltd Business Overview
- 8.8.3 CSL Ltd Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.8.4 CSL Ltd Sickle Cell Disease Drug Product Portfolio
- 8.8.5 CSL Ltd Recent Developments
- 8.9 CRISPR Therapeutics
- 8.9.1 CRISPR Therapeutics Company Information
- 8.9.2 CRISPR Therapeutics Business Overview
- 8.9.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.9.4 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
- 8.9.5 CRISPR Therapeutics Recent Developments
- 8.10 Calimmune Inc
- 8.10.1 Calimmune Inc Company Information
- 8.10.2 Calimmune Inc Business Overview
- 8.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Calimmune Inc Sickle Cell Disease Drug Product Portfolio
- 8.10.5 Calimmune Inc Recent Developments
- 8.11 Bristol-Myers Squibb Co
- 8.11.1 Bristol-Myers Squibb Co Company Information
- 8.11.2 Bristol-Myers Squibb Co Business Overview
- 8.11.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
- 8.11.5 Bristol-Myers Squibb Co Recent Developments
- 8.12 bluebird bio Inc
- 8.12.1 bluebird bio Inc Company Information
- 8.12.2 bluebird bio Inc Business Overview
- 8.12.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.12.4 bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
- 8.12.5 bluebird bio Inc Recent Developments
- 8.13 Bioverativ Inc
- 8.13.1 Bioverativ Inc Company Information
- 8.13.2 Bioverativ Inc Business Overview
- 8.13.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
- 8.13.5 Bioverativ Inc Recent Developments
- 8.14 Bio Products Laboratory Ltd
- 8.14.1 Bio Products Laboratory Ltd Company Information
- 8.14.2 Bio Products Laboratory Ltd Business Overview
- 8.14.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
- 8.14.5 Bio Products Laboratory Ltd Recent Developments
- 8.15 ArQule Inc
- 8.15.1 ArQule Inc Company Information
- 8.15.2 ArQule Inc Business Overview
- 8.15.3 ArQule Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.15.4 ArQule Inc Sickle Cell Disease Drug Product Portfolio
- 8.15.5 ArQule Inc Recent Developments
- 8.16 Annexin Pharmaceuticals AB
- 8.16.1 Annexin Pharmaceuticals AB Company Information
- 8.16.2 Annexin Pharmaceuticals AB Business Overview
- 8.16.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.16.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
- 8.16.5 Annexin Pharmaceuticals AB Recent Developments
- 8.17 Angiocrine Bioscience Inc
- 8.17.1 Angiocrine Bioscience Inc Company Information
- 8.17.2 Angiocrine Bioscience Inc Business Overview
- 8.17.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.17.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
- 8.17.5 Angiocrine Bioscience Inc Recent Developments
- 8.18 Addmedica SAS
- 8.18.1 Addmedica SAS Company Information
- 8.18.2 Addmedica SAS Business Overview
- 8.18.3 Addmedica SAS Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.18.4 Addmedica SAS Sickle Cell Disease Drug Product Portfolio
- 8.18.5 Addmedica SAS Recent Developments
- 8.19 Acceleron Pharma Inc
- 8.19.1 Acceleron Pharma Inc Company Information
- 8.19.2 Acceleron Pharma Inc Business Overview
- 8.19.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Value and Gross Margin (2021-2026)
- 8.19.4 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
- 8.19.5 Acceleron Pharma Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Sickle Cell Disease Drug Value Chain Analysis
- 9.1.1 Sickle Cell Disease Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Sickle Cell Disease Drug Sales Mode & Process
- 9.2 Sickle Cell Disease Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Sickle Cell Disease Drug Distributors
- 9.2.3 Sickle Cell Disease Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst